These preclinical studies and ongoing clinical trial data suggest impeding the anti-apoptotic nature of BCL-XL, and perhaps other BCL-2 family members, may improve JAK2 inhibitor therapy for myelofibrosis, and perhaps other MPN, patients (Fig. 1). This evidence concerns the gene BCL2 and myeloproliferative neoplasm.